BioPerfectus successfully hosted a global webinar on June 19, 2025, titled “World’s First HPV Genotyping & Normalized Quantification Assay: Clinical Breakthroughs and Evidence-Based Impact.” The event attracted hundreds of healthcare professionals from over 30 countries, including clinicians, scientists, and public health leaders, demonstrating the growing global urgency to innovate cervical cancer prevention.

The keynote presentation was delivered by Prof. Pengming Sun, MD, PhD, Vice President of Fujian Maternal and Child Health Hospital and member of the WHO Guideline Development Group. Prof. Sun introduced a new screening strategy that combines HPV genotyping with standardized viral load quantification, a novel diagnostic approach developed by BioPerfectus.

“Cervical cancer is preventable and curable—but only if we improve how we screen,” Prof. Sun emphasized. “Genotype-specific viral load offers the clinical precision we’ve been missing.”

This innovative assay, already approved by multiple global regulatory bodies, enables:

- More accurate identification of high-risk HPV infections

- Better triage decisions for HPV-positive women

- A streamlined, single-visit screening approach

Prof. Sun’s presentation was further supported by real-world data from large-scale trials such as CHIMUST and FCLSCs, which confirmed the assay’s high specificity, strong sensitivity, and adaptability across diverse healthcare settings.

The webinar reinforced the growing international consensus on the role of HPV viral load as a vital biomarker. Leading organizations including the FDA, ESGO, EFC, and public health authorities in France and China now recognize the clinical significance of viral load quantification in cervical cancer screening and patient management.

The event concluded with a live Q&A session that drew high engagement from attendees worldwide. Participants raised questions about viral load cutoff thresholds, screening program implementation, and integration with existing cytology protocols in their regions. The level of engagement highlighted the strong clinical interest and the practical need for tools that offer standardization, accessibility, and scientific validation.

“We are proud to help move cervical cancer screening into a more precise, equitable future.” said a BioPerfectus spokesperson. BioPerfectus HPV solution is currently in use across more than 90 countries, supported by approvals from regulatory authorities such as China NMPA, CE, MHRA, Thai FDA, and SAPHRA. It has already benefited over 10 million women and continues to expand in reach and impact.

The company remains committed to providing ongoing training, scientific education, and implementation support for healthcare teams integrating genotype-specific viral load testing into their screening protocols. As a pioneer in molecular diagnostics, BioPerfectus is not only delivering technology—it is helping shape the future of global cervical cancer screening.